Compare JKS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JKS | NEO |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2010 | 1999 |
| Metric | JKS | NEO |
|---|---|---|
| Price | $24.22 | $11.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $28.59 | $12.56 |
| AVG Volume (30 Days) | 766.5K | ★ 1.9M |
| Earning Date | 11-17-2025 | 10-28-2025 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,641,756,390.00 | $709,162,000.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | $31.11 | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $13.42 | $4.72 |
| 52 Week High | $31.88 | $19.12 |
| Indicator | JKS | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 62.11 |
| Support Level | $24.01 | $11.66 |
| Resistance Level | $26.48 | $12.26 |
| Average True Range (ATR) | 1.54 | 0.49 |
| MACD | -0.37 | 0.04 |
| Stochastic Oscillator | 4.45 | 72.85 |
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.